Genzyme Revises Fabrazyme Phase IV Proposal In Bid For April Approval
Executive Summary
Genzyme's proposal for completing its Phase IV Fabrazyme study is the kind of innovative drug development proposal that FDA Commissioner McClellan is encouraging, Genzyme CEO Henri Termeer suggested during a March 5 conference call
You may also be interested in...
The Mark Of McClellan? Commissioner Downplays Role In Drug Approvals
FDA Commissioner McClellan's direct contribution to product reviews is limited to drawing on a network of outside experts to assist in decisions, the commissioner suggested during a May 16 Manhattan Institute-sponsored roundtable with buy-side analysts
The Mark Of McClellan? Commissioner Downplays Role In Drug Approvals
FDA Commissioner McClellan's direct contribution to product reviews is limited to drawing on a network of outside experts to assist in decisions, the commissioner suggested during a May 16 Manhattan Institute-sponsored roundtable with buy-side analysts
Fabrazyme Approved; FDA Weighing What Confirmatory Data Will Be Needed
FDA has set a deadline of Jan. 31, 2004 for Genzyme's Fabrazyme confirmatory placebo-controlled trial following its April 24 approval